JPWO2023133280A5 - - Google Patents

Info

Publication number
JPWO2023133280A5
JPWO2023133280A5 JP2024540882A JP2024540882A JPWO2023133280A5 JP WO2023133280 A5 JPWO2023133280 A5 JP WO2023133280A5 JP 2024540882 A JP2024540882 A JP 2024540882A JP 2024540882 A JP2024540882 A JP 2024540882A JP WO2023133280 A5 JPWO2023133280 A5 JP WO2023133280A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
muc16
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502061A (ja
JP2025502061A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/010326 external-priority patent/WO2023133280A1/en
Publication of JP2025502061A publication Critical patent/JP2025502061A/ja
Publication of JPWO2023133280A5 publication Critical patent/JPWO2023133280A5/ja
Publication of JP2025502061A5 publication Critical patent/JP2025502061A5/ja
Pending legal-status Critical Current

Links

JP2024540882A 2022-01-07 2023-01-06 再発性卵巣癌を、二重特異性抗muc16×抗cd3抗体単独で、または抗pd-1抗体と組み合わせて治療する方法 Pending JP2025502061A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263297333P 2022-01-07 2022-01-07
US63/297,333 2022-01-07
US202263342542P 2022-05-16 2022-05-16
US63/342,542 2022-05-16
US202263394483P 2022-08-02 2022-08-02
US63/394,483 2022-08-02
US202263421541P 2022-11-01 2022-11-01
US63/421,541 2022-11-01
PCT/US2023/010326 WO2023133280A1 (en) 2022-01-07 2023-01-06 Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Publications (3)

Publication Number Publication Date
JP2025502061A JP2025502061A (ja) 2025-01-24
JPWO2023133280A5 true JPWO2023133280A5 (https=) 2026-01-13
JP2025502061A5 JP2025502061A5 (https=) 2026-01-13

Family

ID=85199214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540882A Pending JP2025502061A (ja) 2022-01-07 2023-01-06 再発性卵巣癌を、二重特異性抗muc16×抗cd3抗体単独で、または抗pd-1抗体と組み合わせて治療する方法

Country Status (9)

Country Link
US (1) US20230312718A1 (https=)
EP (1) EP4460520A1 (https=)
JP (1) JP2025502061A (https=)
KR (1) KR20240130137A (https=)
AU (1) AU2023204751A1 (https=)
CA (1) CA3242629A1 (https=)
IL (1) IL313864A (https=)
MX (1) MX2024008055A (https=)
WO (1) WO2023133280A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194596A (en) * 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
TW202542187A (zh) * 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MY194596A (en) 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法

Similar Documents

Publication Publication Date Title
US20250074985A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TWI890661B (zh) 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
CN108602889A (zh) 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP2020100630A (ja) オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法
JPWO2019246356A5 (https=)
JP2025509567A (ja) 再発性類上皮肉腫を、二重特異性抗MUC16x 抗CD3抗体単独で、または抗PD-1抗体と組み合わせて治療する方法
JPWO2021113701A5 (https=)
JPWO2023133280A5 (https=)
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
RU2024122332A (ru) СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕГО РАКА ЯИЧНИКА С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХ АНТИТЕЛ К MUC16 x CD3 ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1
JPWO2023177772A5 (https=)
RU2024129390A (ru) СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕЙ ЭПИТЕЛИОИДНОЙ САРКОМЫ С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХАНТИТЕЛ ПРОТИВ MUC16 x CD3 САМИХ ПО СЕБЕ ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ ПРОТИВ PD-1
US20220389088A1 (en) Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use
HK40114667A (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
WO2025128652A1 (en) Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
CN120019073A (zh) 一种治疗实体瘤的方法
RU2026105218A (ru) Способы лечения светлоклеточного рака почек с помощью биспецифических антител к psma/cd28
RU2026105219A (ru) Способы лечения метастатического кастрационно-резистентного рака предстательной железы с помощью биспецифических антител к psma/cd28
JP2021518393A5 (https=)
TW202608479A (zh) 治療具有類風濕性關節炎的個體中疼痛之組成物及方法
TH2101002581A (th) วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn
JPWO2023092062A5 (https=)
HK40049064B (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
HK40049064A (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies